^
    2d
    A gastrointestinal stromal tumour in the distal ileum-a rare presentation in Saudia Arabia: case report. (PubMed, Front Surg)
    Furthermore, research must investigate epidemiological issues, therapeutic methods, and follow-up procedures in Saudi Arabia. Guidelines for managing and following up on these cases should be developed based on the agreed-upon processes.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD34 (CD34 molecule)
    |
    imatinib
    2d
    Rare extra-gastrointestinal stromal tumor of the vulva: a case report. (PubMed, Gynecol Oncol Rep)
    Postoperatively, the patient recovered well and was treated with adjuvant imatinib...Comprehensive workup, wide excision with negative margins, and targeted therapy are essential. Increased awareness and reporting are needed to guide management.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD34 (CD34 molecule) • ANO1 (Anoctamin 1)
    |
    imatinib
    7d
    Reduced levels of ITGB1 cause activation of p38MAPK-ERK-LYN axis of BCR::ABL1 signaling despite inactivation of the oncoprotein by imatinib - novel resistance mechanism in blast crisis of chronic myeloid leukemia unraveled. (PubMed, Cell Commun Signal)
    Thus, reduction in level of ITGB1 in resistant cells leads to activation of ERK and p38MAPK belonging to BCR::ABL1 pathway, despite inactivation of BCR::ABL1, which in turn leads to activation of LYN. Together, these kinases activate members of vital pro-survival pathways, thereby imparting imatinib resistance in CML-BC cells.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • CD34 (CD34 molecule) • LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase) • ITGB1 (Integrin Subunit Beta 1)
    |
    imatinib
    7d
    ASCENdANT: Asciminib in HER2+ Breast Cancer Brain Metastases (clinicaltrials.gov)
    P1/2, N=42, Not yet recruiting, Duke University | Initiation date: Feb 2026 --> Jul 2026
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Herceptin (trastuzumab) • Scemblix (asciminib)
    7d
    IMATI-10-25: An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Imatinib Mesylate Tablets 400 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Glivec (Imatinib mesylate) Coated tablets 400 mg, Produced by Novartis Pharma Produktions GmbH, Wehr, Germany or Novartis Pharmaceutical Manufacturing LLC, Ljubljana; Imported and Registered by Novartis Biosciences SA, Prof. Vicente Rao Avenue, 90, Sao Paulo SP, CNPJ: 56.994.502/0001-30, Brazilian Industry, in healthy adult, human subjects under fed condition. (2025-524935-38-00)
    P1, N=28, Not yet recruiting, Sun Pharmaceutical Industries Limited
    New P1 trial
    |
    imatinib
    10d
    Small bowel volvulus revealing advanced jejunal gastrointestinal stromal tumor with diffuse metastases: a case report. (PubMed, Ann Med Surg (Lond))
    The patient recovered uneventfully and was started on treatment with imatinib mesylate...GISTs should be considered in cases of unexplained SBV. This case emphasizes the diagnostic challenges, the need for prompt surgical palliation, and the role of systemic tyrosine kinase inhibitors in advanced presentation of GIST.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • ANO1 (Anoctamin 1)
    |
    imatinib
    10d
    Small bowel GIST harboring concurrent KIT exon 9 duplication and SDHC mutation: A case report. (PubMed, Oncotarget)
    Activating mutations in KIT or PDGFRA characterize most GISTs and confer sensitivity to imatinib, whereas succinate dehydrogenase (SDH)–deficient GISTs lack these mutations and are typically imatinib resistant...Pathology demonstrated spindle cell GIST with significant treatment effect and retained SDHB expression. This case suggests that oncogenic KIT signaling may remain the dominant driver of GIST behavior despite the presence of a germline SDHC mutation and highlights the importance of integrated molecular interpretation in GIST management.
    Journal
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • SDHC (Succinate Dehydrogenase Complex Subunit C)
    |
    KIT mutation • KIT exon 9 mutation • PDGFRA mutation
    |
    imatinib
    10d
    Targeting the Unmet Need in Gastrointestinal Stromal Tumors: A Contemporary Review of Investigational Clinical Trials and Therapeutic Landscape. (PubMed, Pharmaceuticals (Basel))
    Although tyrosine kinase inhibitors (TKIs), particularly imatinib, have substantially improved outcomes, most patients with advanced disease eventually develop resistance, resulting in disease progression...Molecular stratification and personalized approaches dominate ongoing research, but evidence generation remains limited by small sample sizes and slow recruitment. Future trials integrating innovative therapeutic platforms and patient-centered outcomes are essential to improve long-term disease control and quality of life.
    Review • Journal • IO biomarker
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    KIT mutation • PDGFRA mutation
    |
    imatinib
    10d
    Targeting Apoptosis-Resistant Proliferation: Imatinib-Based Combinations Induce Durable Cytostatic Arrest in 3D Endometrial Cancer Spheroids. (PubMed, Biomedicines)
    Imatinib-based combinations suppress 3D endometrial cancer growth predominantly through sustained cell cycle arrest rather than apoptosis induction. Targeting apoptosis-resistant proliferation through cytostatic mechanisms may represent a complementary therapeutic strategy for hormone-responsive endometrial cancer and warrants further translational evaluation.
    Journal
    |
    ANXA5 (Annexin A5)
    |
    imatinib
    11d
    Zebularine Boosts Imatinib Efficacy in Cells of Colorectal Cancer via Wnt-Survivin-P-Glycoprotein Pathway. (PubMed, J Biochem Mol Toxicol)
    Both IM and ZEB combination showed promise in the management of CRC by inducing oxidative stress, promoting apoptosis, and modulating critical genes involved in metastasis and apoptosis. Further investigation will be needed to verify their application in preclinical and clinical settings.
    Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • BCL2 (B-cell CLL/lymphoma 2) • BIRC5 (Baculoviral IAP repeat containing 5) • MMP2 (Matrix metallopeptidase 2) • CASP9 (Caspase 9) • MMP9 (Matrix metallopeptidase 9)
    |
    imatinib
    11d
    Final results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial. (PubMed, Lancet Haematol)
    In this setting, Peg-IFN combined with nilotinib induced higher initial rates of MR4·5 compared to TKI monotherapy, despite additional side effects. The onset of psychiatric events might promote immediate cease of Peg-IFN and psychiatrist advice Whether this early molecular response translates into sustained treatment-free survival should be studied in a randomised trial sufficiently powered for this outcome.
    Clinical • P3 data • Journal
    |
    ABL1 (ABL proto-oncogene 1)
    |
    nilotinib
    11d
    The novel integrin-linked kinase inhibitor nilotinib suppresses cancer progression by promoting ubiquitylation of autoimmune regulator in oesophageal squamous cell carcinoma. (PubMed, Anticancer Drugs)
    Cycloheximide chase assays indicated accelerated AIRE protein degradation, while MG132 partially rescued AIRE levels, implicating proteasome-dependent degradation. Overall, Nilotinib suppresses ESCC progression by inhibiting ILK and destabilising AIRE, suggesting its potential as a targeted therapy for ILK-positive ESCC.
    Journal • PARP Biomarker
    |
    MMP2 (Matrix metallopeptidase 2) • CASP3 (Caspase 3) • MMP9 (Matrix metallopeptidase 9) • PCNA (Proliferating cell nuclear antigen) • ILK (Integrin Linked Kinase) • MT-CO2 (Mitochondrially Encoded Cytochrome C Oxidase II)
    |
    nilotinib